MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4103/ijph.ijph_505_23

Медицинская библиотека · Indian journal of public health · 2025

Comparing ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (Covishield) and BBV152; Bharat Biotech COVID-19 Vaccine (Covaxin) for COVID-19: Reports of Adverse Events Following Vaccination among the Indian Population.

Kaur Sukhpal, Rohilla Latika, Kayina Choro Athiphro, Kaur Jasvir, Kaur Gurpreet, Walia Anjani, Kumar Pramod, Singh Ajay, Saini Sushma, Soni Shiv Lal, Malhotra Pankaj

СтатьяСравнительное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

COVID-19 is declared a global pandemic by the WHO; vaccines were the need of the hour to reduce mortality and return to some form of normal life. The Indian government provides two vaccines as per the program; ChAdOx1 nCoV-19 and BBV152; Bharat Biotech COVID-19 vaccine. However, vaccine hesitancy is a major public health concern.

OBJECTIVE

To evaluate the adverse events following immunization (AEFIs) after COVID-19 vaccination. The safety profile of ChAdOx1 nCoV-19 and BBV152 vaccine was also studied.

MATERIALS AND

METHODS

This was a large-scale, cross-sectional survey. Beneficiaries who had their vaccination in the past 2 weeks were sent an online survey performa regarding AEFIs after COVID-19 vaccine.

RESULTS

Out of 2311 participants, 58% received ChAdOx1-nCoV-19 and 42% received BBV152 COVID-19 vaccine, with the mean ± standard deviation age (years) of 36.3 ± 14.5 and 16.9 ± 4.07, respectively. The previous history of COVID-19 infection was reported in 7% of the participants. In the ChAdOx1-nCoV-19 group, 85.3% participants reported at least one adverse reaction, with pain at site being the most common, followed by fever, fatigue, and feeling of unwellness. In the BBV152 group, 17% reported adverse reaction, with pain site being the most common, followed by tenderness, fatigue, and feeling of unwellness. In the BBV152 group, a significant positive association was observed between AEFIs and age. In the ChAdOx1-nCoV-19 group, age was marginally associated with AEFIs. AEFIs were more after first dose (121 vs. 43, P < 0.001, adjusted odds ratio (OR) =3.39 [95% confidence interval [CI]: 2.24-5.11], P < 0.001) among elderly (adjusted OR = 0.60, 95% CI: 0.36-0.99, P = 0.047) and women (721 vs. 423, P = 0.001, adjusted OR = 1.68 [95% CI: 1.24-2.29], P = 0.001).

CONCLUSION

Our study observed that both ChAdOx1 nCoV-19 and BBV152 have a favorable safety profile without serious AEFIs in any of the beneficiaries.

Для цитирования: Kaur Sukhpal, Rohilla Latika, Kayina Choro Athiphro, Kaur Jasvir, Kaur Gurpreet, Walia Anjani, Kumar Pramod, Singh Ajay, Saini Sushma, Soni Shiv Lal, Malhotra Pankaj. Comparing ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (Covishield) and BBV152; Bharat Biotech COVID-19 Vaccine (Covaxin) for COVID-19: Reports of Adverse Events Following Vaccination among the Indian Population.. Indian journal of public health. 2025. DOI: 10.4103/ijph.ijph_505_23.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.